Effect of Sacubactril Valsartan Sodium Tablets in the Treatment of Chronic Heart Failure
Objective To analyze the effect of sacubactril valsartan sodium tablets in the treatment of chronic heart failure.Methods A total of 186 patients with chronic heart failure admitted to the People's Hospital of Liupanshui City from December 2021 to December 2022 were included in the study.They were divided into new group and traditional group with random number table method,93 cases in each group.The traditional group was treated with enalapril,while the new group was treated with sacubactril valsartan sodium tablets.The cardiac function index[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)and brain natriuretic peptide(BNP)],treatment effect and prognosis of the two groups were compared.Results After intervention,LVEF level[(48.36±5.29)%]in the new group was higher than that in the traditional group[(46.29±5.26)%],the levels of LVESD,LVEDD and BNP[(38.63±4.25)mm,(50.26±4.93)mm,(133.36±12.25)ng/L]were lower than those of the traditional group[(41.26±2.25)mm,(54.26±4.29)mm,(159.63±20.36)ng/L],the difference was statistically significant(P<0.05).The total effective rate of the new group(97.85%)was higher than that of the traditional group(82.80%),and the difference was statistically significant(P<0.05).The rates of readmitted hospital admission and adverse cardiovascular events(11.83%,16.13%)in the new group were lower than those in the traditional group(32.26%,37.63%),and the differences were statistically significant(P<0.05).Conclusion Sacubactril valsartan sodium tablets is effective in the treatment of chronic heart failure,which can improve cardiac function,reduce readmission rate and the incidence of adverse cardiovascular events.
万方数据
维普
